|
Jul 26
|
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis
|
|
Jan 15
|
GENFIT Announces 2024 Financial Calendar
|
|
Jan 11
|
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
|
|
Dec 8
|
GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)
|
|
Dec 7
|
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
|
|
Dec 6
|
GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials
|
|
Apr 27
|
GENFIT Announces Publication of Extra-Financial Performance Report 2022
|